JOURNEY MEDICAL CORP (DERM)

US48115J1097 - Common Stock

5.35  -0.13 (-2.37%)

After market: 5.22 -0.13 (-2.43%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

JOURNEY MEDICAL CORP

NASDAQ:DERM (12/6/2024, 8:00:01 PM)

After market: 5.22 -0.13 (-2.43%)

5.35

-0.13 (-2.37%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month13.83%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap79.66M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
Short Float %
Short Ratio
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

DERM Daily chart

Company Profile

Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company is headquartered in Scottsdale, Arizona and currently employs 58 full-time employees. The company went IPO on 2021-11-12. The firm is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. The company sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.

Company Info

JOURNEY MEDICAL CORP

9237 E Via De Ventura Blvd., Suite 105, Suite 105

Scottsdale ARIZONA 94025

P: 14804346670

CEO: Thomas G. Wiggans

Employees: 41

Website: https://journeymedicalcorp.com/

DERM News

ChartMill News Image9 days ago - ChartmillDiscover the top movers in Friday's pre-market session and stay informed about market dynamics.

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

News Image25 days ago - Journey Medical CorporationJourney Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults;...

News Imagea month ago - Journey Medical CorporationJourney Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T....

News Imagea month ago - Journey Medical CorporationJourney Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral...

News Image2 months ago - ACCESSWIRESWK Holdings Provides Portfolio Update
News Image2 months ago - Journey Medical CorporationJourney Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage...

DERM Twits

Here you can normally see the latest stock twits on DERM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example